Cofco Biotechnology (000930.SZ) announced the performance forecast for the first half of 2024. According to preliminary calculations by the finance department, net income attributable to shareholders of the listed company in the first half of 2024 is expected to be between 53 million yuan and 68 million yuan, an increase of 116% to 120% compared to the same period last year. Net income after deducting non-recurring gains and losses is expected to be between 16 million yuan and 20 million yuan, an increase of 104%-106% over the same period last year. The basic earnings per share is expected to be 0.0291 yuan/share-0.0371 yuan/share.
In the first half of 2024, the company adopted operating strategies such as "slow purchasing and fast sales" and "combination of futures and spot", grasped the purchasing rhythm, reduced raw material costs, continuously promoted system low cost, intensified efforts to tap potential and reduce consumption, and made steady progress in its operation.